

Posters

Vaccine Technology

June 25-30, 2006

Casa Magna Marriott Puerto Vallarta Resort

Puerto Vallarta, Mexico

Tel: 52-322-226-0000

Fax: 52-322-226-0060

Co-Chairs:

John G. Auninš, Ph.D.

Executive Director, Fermentation & Cell Culture, Merck & Co., Inc.

Barry C. Buckland, Ph.D.

Vice President, Bioprocess R&D, Merck & Co., Inc.

Emilio A. Emini, Ph.D.

Executive Vice President, Wyeth

Jerald C. Sadoff, M.D.

CEO, Aeras Global TB Vaccine Foundation

ECI

Engineering Conferences International

6 MetroTech Center

Brooklyn, NY 11201, USA

Phone: 1-718-260-3743, Fax: 1-718-260-3754

www.engconfintl.org - info@eci.poly.edu

1. **Development of an oral vaccine based on recombinant adenovirus**
Tiago B. Ferreira
ITQB/IBET, Oeiras, Portugal
2. **Optimisation of a vaccine candidate against Heartwater**
Isabel Marcelino
ITQB/IBET, Oeiras, Portugal
3. **Infection Strategy Analysis and MOI Optimization in Rotavirus VLPs Production using a detailed Structured/Segregated Mathematical Model**
António Roldão
IBET/ITQB, Portugal
4. **Development of a Protein-Free, Chemically Defined Cell Culture Medium for the Production of HIV from HUT-78 Cells**
Bjorn K. Lydersen
Immune Response Corporation, USA
5. **Optimization of Serum-Free Media for EB14 Cell Growth and Viral Production**
Coleen McCormick
SAFC Biosciences, USA
6. **Development of a Bacterial Ghost Vaccine for Bacillus anthracis**
Vito G. DeVecchio
Vital Probes, Inc., USA
7. **Peptide Based ECLI Universal Influenza Vaccine**
Sam Chou
Lincrogen, Inc., USA
8. **Vaccines in a Tablet Form**
Gilad Gallili
Biological Laboratories Teva (Abic Vet.), Israel
9. **Rapid Vaccine Development using Microwell Based Platforms**
Tarit K. Mukhopadhyay
The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, United Kingdom
10. **Increased CD4+ T cell-mediated antitumor response by hybridization of an MHC class II HER-2/neu epitope with li-Key**
Eric von Hofe
Antigen Express, Inc., USA
11. **Establishment of a New Analytical Tool for Varicella Manufacturing Process**
Mario Gorziglia
Merck and Co., Inc. Viral Vaccine Technology and Engineering, USA

12. **Glycosylation of Influenza A Virus Hemagglutinin**
Jana Schwarzer, Udo Reichel
Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Germany
13. **An inducible fed-batch fermentation process for scale-up and production of DNA vaccines and gene medicines**
Aaron E. Carnes
Nature Technology Corporation, USA
14. **A Systems Approach to Optimization of Virus Production in Animal Component-Free Medium**
Terrell K. Johnson
SAFC-Biosciences, USA
15. **Genetic Stability of Leningrad-3 Attenuated Live Mumps Vaccine Strain during Vaccine Production in Russia**
George Ignatyev
SRC VB 'Vector', Russia
16. **A new strategy for the preparative purification of rotavirus-like particles produced by the insect-cell baculovirus expression vector system (IC-BEVS)**
Jimmy A. Mena
Universidad Nacional Autónoma de México, Mexico
17. **Evaluation of process alternatives for the intermediate recovery of plasmid DNA**
D.M.F. Prazeres
Centro de Engenharia Biológica e Química, Portugal
18. **Targeting antigens to the immune system: a promising approach to vaccine technology**
G. A. Monteiro
Centro de Engenharia Biológica e Química, Instituto Superior Técnico, Portugal
19. **Rabies Virus As An Immunostimulatory Carrier Molecule For Vaccination Against Anthrax**
Mary Ellen Smith
Thomas Jefferson University, USA
20. **Plasmid DNA processing for gene therapy and DNA vaccination: studies on the membrane sterilisation filtration step**
Simyee Kong, M. Susana Levy
University College London, UK
21. **Quantitation of infective viral particles by capillary cytometry**
M. Susana Levy
University College London, UK

- 22. Levels of Specific peptide-HLA Class I Complex rather than TAA Expression Determines Tumor Cell Susceptibility to CTL Killing**
Jon A. Weidanz
Receptor Logic, Ltd., USA
- 23. Direct Epitope Validation using monoclonal TCR mimic Antibodies**
Jon A. Weidanz
Receptor Logic, Ltd., USA
- 24. Lectin-affinity purification of cell culture derived human Influenza A viruses**
Lars Opitz, Bernd Kalbfouss
Max-Planck-Institute for Dynamics of Complex Technical Systems, Germany
- 25. Purification of a Retroviral vector intended for Gene Therapy**
Teresa Rodrigues, Paula Alves, Manuel Carrondo
Instituto de Biologia Experimental e Tecnologica (IBET), Portugal
- 26. Experimental design for optimization the PlasmidSelect plasmid purification process**
Hans Blom, Mia Bångtsson
GE Healthcare Bio-Sciences AB, Sweden
- 27. High Throughput validation of predicted T-cell epitopes conserved between Variola and Vaccinia: Development of a novel immunome based Smallpox vaccine**
Daniel Rivera
EpiVax, Inc., USA